CHICAGO – The Pancreatic Cancer Action Network (PanCAN) said Thursday that it has chosen Seven Bridges to build a customized health data platform to support pancreatic cancer research.
This platform will integrate longitudinal multiomic molecular, clinical, and outcomes data generated through PanCAN's research and clinical programs and serve as a hub for researchers to collaborate on analyses to inform drug discovery, according to Boston-based Seven Bridges. Data will be deidentified to satisfy regulatory requirements, the company said.
"Open sharing of data and collaboration across the pancreatic cancer research community are the keys to moving the needle in our fight against the world's toughest cancer," PanCAN Chief Data Officer Sudheer Doss said in a statement.
Seven Bridges Chief Scientific Officer Brandi Davis-Dusenbery said that this platform will make PanCAN's data stores more widely accessible to researchers. "With accelerated access to these data, researchers will be able to transform insights into action through the discovery of new treatments based on novel disease targets, biomarkers, or molecular pathways as well as methods for improving clinical practice such as best practices for standard of care or improved patient support," she said.